

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4959165

| | |
|---|--|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | 04/26/2018 |
| RECEIVING PARTY DATA | |
| Name: | SPERA PHARMA, INC. |
| Street Address: | 17-85, JUSOHONMACHI 2-CHOME, YODOGAWA-KU |
| City: | OSAKA-SHI, OSAKA |
| State/Country: | JAPAN |
| Postal Code: | 532-0024 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Patent Number: | 7135582 |
| CORRESPONDENCE DATA | |
| Fax Number: | (312)419-9440 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | +1 312 628 5529 |
| Email: | sradu@deninemeyer-law.com |
| Correspondent Name: | VICTORIA FRIEDMAN |
| Address Line 1: | 2 NORTH RIVERSIDE PLAZA, SUITE 1500 |
| Address Line 4: | CHICAGO, ILLINOIS 60606 |
| ATTORNEY DOCKET NUMBER: | 30100-104159PT |
| NAME OF SUBMITTER: | VICTORIA FRIEDMAN |
| SIGNATURE: | /vfr/ |
| DATE SIGNED: | 05/14/2018 |
| This document serves as an Oath/Declaration (37 CFR 1.63). | |
| Total Attachments: 1 source=US_AD#page1.tif | |

ASSIGNMENT

WHEREAS, **TAKEDA PHARMACEUTICAL COMPANY LIMITED**, corporation duly organized under the laws of Japan, and having their principal place of business at **1-1, DOSHOMACHI 4-CHOME, CHUO-KU, OSAKA 541-0045, JAPAN**, is the owner of an entire right, title and interest in the invention listed below;

Patent No. 7,135,582 issued on November 14, 2006

Title: Transition Metal Complex Having Diphosphine Compound as Ligand

Assignment Reel/Frame: 017333/0030 recorded on May 27, 2005

WHEREAS, **TAKEDA PHARMACEUTICAL COMPANY LIMITED**, hereinafter referred to as **ASSIGNOR**, is desirous of assigning its entire right, title and interest in said U.S. Letters Patent to **SPERA PHARMA, Inc.**, hereinafter **ASSIGNEE**;

WHEREAS, **SPERA PHARMA, Inc.**, a corporation duly organized under the laws of Japan and having its principal place of business at **17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-0024 JAPAN**, hereinafter referred to as **ASSIGNEE**, is desirous of acquiring the entire right, title and interest as held by **ASSIGNOR** in, to and under the said U.S. Letters Patent;

NOW, THEREFORE, in consideration of and in exchange for the sum of One Dollar (\$1.00) and other good and valuable consideration, receipt of which is hereby acknowledged, the said Assignor has sold, assigned, transferred and set over, and does hereby sell, assign, transfer and set over to the said Assignee, its entire right, title and interest of said Letters Patents; the same to be held and enjoyed by the said Assignee, for its own use and enjoyment and that of its successors, assigns and other legal representatives, to the end of the term or terms for which Letters Patent of the United States are granted or reissued or reexamined as fully and entirely as the same would have been held and enjoyed by the said Assignor, if this assignment and sale had not been made, together with all claims for damages by reason of past infringement of the said Letters Patent, with the right to sue for, and collect the same for its own use and behalf, and for the use and behalf of its successors, assigns, or other legal representatives.

IN WITNESS WHEREOF, the undersigned **ASSIGNOR** has hereunto set hand and seal
this 26th day of April, 2018.

Assignor : **TAKEDA PHARMACEUTICAL COMPANY LIMITED**

Signature of Representative :


Hiroya OKUMURA, Global Head of IP